SCHEMBL96178

SCHEMBL96178

[CH2]c1ccc(NS(=O)(=O)c2ccccc2C(=O)OC)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.63
MEN1 O00255 1/20 0.63
MAPT P10636 1/20 0.57
PTPN2 P17706 1/20 0.56
PTPN1 P18031 1/20 0.56
PTPN5 P54829 1/20 0.56
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA5A P35218 1/20 0.55
CA9 Q16790 1/20 0.55
NPC1 O15118 1/20 0.53
GAA P10253 1/20 0.53
BRD4 O60885 3/20 0.53
SLC40A1 Q9NP59 1/20 0.51
MMP2 P08253 1/20 0.50
MMP13 P45452 1/20 0.50
ALDH1A1 P00352 1/20 0.46
HPGD P15428 2/20 0.46
MAPK10 P53779 1/20 0.46
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2741010 0.88 NPC1 (0.66) KMT2AMEN1MAPTPTPN2PTPN1
SCHEMBL12167785 0.86 MMP2 (0.67) KMT2AMEN1MAPTPTPN2PTPN1
SCHEMBL14150131 0.86 MEN1 (0.63) KMT2AMEN1MAPTPTPN2PTPN1
SCHEMBL28765969 0.85 MMP2 (0.49) KMT2AMEN1MAPTPTPN2PTPN1
SCHEMBL14106146 0.82 KMT2A (0.59) KMT2AMEN1MAPTPTPN2PTPN1
SCHEMBL15482267 0.82 MMP2 (0.60) KMT2AMEN1MAPTPTPN2PTPN1
SCHEMBL10765395 0.79 MEN1 (0.56) KMT2AMEN1MAPTPTPN2PTPN1
SCHEMBL17078023 0.78 KMT2A (0.57) KMT2AMEN1MAPTPTPN2PTPN1
SCHEMBL95649 0.78 SLC22A12 (0.55) KMT2AMEN1PTPN2PTPN1PTPN5
SCHEMBL1050952 0.77 MEN1 (0.66) KMT2AMEN1MAPTNPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB KMT2A 1059/4885MEN1 4401/4885MAPT 4112/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 KMT2A 2732/4885MEN1 3912/4885MAPT 4773/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 KMT2A 2732/4885MEN1 3912/4885MAPT 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.